Thymosin Alpha-1
Ta1 / Zadaxin / Thymalfasin
Thymosin Alpha-1 (Ta1) is a 28-amino acid immunomodulatory peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is approved in over 35 countries under the brand name Zadaxin for the treatment of chronic hepatitis B and C, and holds FDA orphan drug designation for hepatocellular carcinoma and DiGeorge syndrome. Ta1 acts as a pleiotropic immune modulator, enhancing dendritic cell maturation, T-cell differentiation, and NK cell cytotoxicity while simultaneously dampening excessive inflammatory responses.
作用機序
Naturally occurring 28-amino-acid thymic peptide that modulates T-cell maturation and function. Activates toll-like receptors (TLR2, TLR9), promotes dendritic cell maturation, enhances NK cell cytotoxicity, and shifts Th1/Th2 balance toward Th1-dominant immune responses.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Research protocols use 1.6mg subcutaneously twice weekly. Hepatitis B/C protocols: 1.6mg twice weekly for 6-12 months. Immune support protocols: 1.6mg 2-3 times weekly for 2-4 weeks.
研究ノート
Clinical Research Status
Thymosin Alpha-1 (Zadaxin) is approved in 35+ countries including China, India, and throughout Southeast Asia and South America for hepatitis B and as an immune adjuvant. It holds FDA orphan drug designation for hepatocellular carcinoma, DiGeorge syndrome, and as an adjunct to influenza vaccine in immunocompromised patients, but has not achieved full FDA approval. Over 4,500 patients have been studied in controlled clinical trials spanning hepatitis, cancer immunotherapy, vaccine adjuvant therapy, and sepsis. Recent research has explored its use in severe COVID-19 infections, with retrospective studies showing reduced mortality in critically ill patients.
Key Published Findings
A meta-analysis of 7 randomized controlled trials published in the Journal of Viral Hepatitis showed Ta1 combined with interferon-alpha produced sustained virologic response rates of 50-55% in hepatitis B versus 25-30% for interferon alone. Studies in hepatocellular carcinoma patients demonstrated improved 12-month survival and reduced recurrence when Ta1 was used as adjuvant immunotherapy post-resection. A 2020 retrospective study in severe COVID-19 patients showed Ta1 treatment was associated with reduced mortality (11% vs 30%) and restoration of T-cell counts. Research demonstrates Ta1 activates toll-like receptors (TLR2, TLR9) on dendritic cells, bridging innate and adaptive immune responses.
Safety Profile
Thymosin Alpha-1 has one of the most extensive safety databases among peptide therapeutics, with over 20 years of clinical use across 35+ countries and 4,500+ trial participants. The most common adverse effect is mild injection site discomfort; no significant organ toxicity, autoimmune flares, or immunosuppression rebound has been documented. Unlike interferon or IL-2, Ta1 does not cause flu-like symptoms, myelosuppression, or the severe adverse effects associated with other immunomodulators. It modulates rather than simply stimulates immunity, which may explain the absence of cytokine storm risk even in inflammatory conditions.
Drug Interactions & Contraindications
Ta1 is synergistic with interferon-alpha and is commonly co-administered in hepatitis treatment protocols without adverse interactions. Theoretical caution applies in patients taking immunosuppressive drugs (tacrolimus, cyclosporine) for organ transplants, as Ta1 may counteract immunosuppression. Concurrent use with checkpoint inhibitors (anti-PD-1, anti-CTLA-4) is being studied and may enhance anti-tumor immunity but requires monitoring for immune-related adverse events. No absolute contraindications have been established, though it should be used cautiously in patients with active autoimmune diseases.
Comparison to Related Compounds
Unlike thymosin beta-4 (TB-500), which primarily promotes tissue repair and angiogenesis, Thymosin Alpha-1 is specifically an immune modulator with minimal tissue repair properties. Compared to interferon-alpha, Ta1 achieves similar or superior virologic responses in hepatitis with dramatically fewer side effects and better tolerability. Relative to other immune peptides like LL-37, Ta1 acts more on adaptive immunity (T-cells, dendritic cells) rather than innate antimicrobial defense. Its immunomodulatory (rather than immunostimulatory) profile distinguishes it from IL-2 and colony-stimulating factors, making it safer in inflammatory contexts.
Community Observations
Users typically dose Thymosin Alpha-1 at 1.6 mg subcutaneously, 2-3 times per week, mirroring the clinical trial protocols used for Zadaxin. Many report subjective improvements in recovery from illness, reduced frequency of infections, and improved response to vaccines. It is popular among immunocompromised individuals, those with chronic viral infections, and as part of integrative oncology protocols. The peptide is well-tolerated with virtually no reported adverse effects in community use, consistent with its extensive clinical safety data.
半減期
~2 hours
再構成
Bacteriostatic water (BAC) or sterile water
保存
乾燥粉末
Refrigerate 2-8C up to 36 months.
再溶解
Refrigerate 2-8C. Use within 14 days.
米国法的状況
また知られる名前
よくある質問
Thymosin Alpha-1とは何ですか?
Thymosin Alpha-1 (Ta1) is a 28-amino acid immunomodulatory peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is approved in over 35 countries under the brand name Zadaxin for the treatment of chronic hepatitis B and C, and holds FDA orphan drug designation for hepatocellular carcinoma and DiGeorge syndrome. Ta1 acts as a pleiotropic immune modulator, enhancing dendritic cell maturation, T-cell differentiation, and NK cell cytotoxicity while simultaneously dampening excessive inflammatory responses.
Thymosin Alpha-1はどのように作用しますか?
Naturally occurring 28-amino-acid thymic peptide that modulates T-cell maturation and function. Activates toll-like receptors (TLR2, TLR9), promotes dendritic cell maturation, enhances NK cell cytotoxicity, and shifts Th1/Th2 balance toward Th1-dominant immune responses.
Thymosin Alpha-1の米国での規制状況は?
FDA-approved orphan drug status; approved in 35+ countries
Thymosin Alpha-1の半減期は?
~2 hours
Thymosin Alpha-1の別名は?
Ta1, Zadaxin, Thymalfasin
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む